BB Biotech : Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.40 per share

DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.40 per share (news with additional features) 19.03.2020 / 17:40 The issuer is solely responsible for the content of this announcement. Media Release as of March 19, 2020 Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.40 per share All proposals of BB Biotech AG's Board of Directors were approved by shareholders at its Annual General Meeting held today. In accordance with the Covid-19 Ordinance 2, the voting rights of shareholders were exclusively exercised through the independent proxy as per their instructions, since shareholders were not allowed to attend the meeting in person. Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.40 per share. Payment will be made on March 25, 2020, the record date is March 24, 2020 and the ex-dividend date is March 23, 2020. The Chairman affirmed, "We intend to maintain our current dividend policy, also during the coming years." Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell and Dr. Thomas von Planta to another one-year term of office. Prof. Dr. Dr. Klaus Strein announced last year that he was stepping down from the Board and there did not stand for re-election. The Board of Directors thanks Klaus Strein for his valuable contribution and personal commitment to BB Biotech over the past seven years. Two new directors were elected - Prof. Dr. Mads Krogsgaard Thomsen and, with effect from October 1, 2020, Dr. Susan Galbraith. Susan Galbraith joined AstraZeneca in 2010 and heads its Oncology Research and Early Development Department. She oversaw the successful development of several cancer drugs that have been approved worldwide. She also co-leads the Cambridge Cancer Center Onco-Innovation Group. Susan Galbraith is also on the Board of Directors of Horizon Discovery PLC, a member of the Scientific advisory board of the ICR Cancer Research Center of Excellence and she sits on the AACR Finance Committee as well as the AACR 2020 Annual Meeting Scientific Program Committee. Mads Krogsgaard Thomsen has been with Novo Nordisk since 1991. He has held several executive roles in the company's growth hormone and diabetes research operations. He currently serves as Executive Vice President and Chief Science Officer with responsibility for global drug and device research, CMC and global drug development, regulatory affairs and drug safety. Professor Thomsen has chaired Danish Research Council programs within endocrinology and he is a former president of Denmark's National Academy of Technical Sciences. He is a member of the board of the Symphogen A/S, Denmark, and chaired the governing board of the University of Copenhagen until the end of 2019. Investor Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. [phone] Dr. Silvia Schanz, [e-mail] Maria-Grazia Iten-Alderuccio, [e-mail] Claude Mikkelsen, [e-mail] Media Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. [phone] Tanja Chicherio, [e-mail] TE Communications AG, St. Leonhard-Strasse 45, 9001 St. Gallen, Switzerland, Tel. [phone] Thomas Egger, [e-mail] www.bbbiotech.com Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions. Disclaimer This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers undertake no obligation to update any forward-looking statements as a result of new information, future events or other factors. Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=XOATJQIABA Document title: Media release 19.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English
Company:	BB BIOTECH AG
	Schwertstrasse 6
	8200 Schaffhausen
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.bbbiotech.ch
ISIN:	CH0038389992
WKN:	A0NFN3
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID:	1001787

End of News	DGAP News Service

1001787  19.03.2020